Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the iAccess Alpha Virtual Best Ideas Winter Conference 2024. The event will take place on December 10th and 11th, 2024.
Dr. Amit Kumar, CEO of Anixa, will deliver a presentation on Tuesday, December 10th at 2:00 p.m. EST. The company's management team will be available for one-on-one meetings with qualified investors on Wednesday, December 11th.
The conference, hosted by iAccess Alpha, features companies recommended by an investor network and follows a two-day format with company webcasts on the first day and one-on-one management meetings on the second day.
Anixa Biosciences (NASDAQ: ANIX), un'azienda biotecnologica specializzata nel trattamento e nella prevenzione del cancro, ha annunciato la sua partecipazione al iAccess Alpha Virtual Best Ideas Winter Conference 2024. L'evento si svolgerà il 10 e 11 dicembre 2024.
Il Dr. Amit Kumar, CEO di Anixa, terrà una presentazione martedì 10 dicembre alle 14:00 EST. Il team di gestione dell'azienda sarà disponibile per incontri individuali con investitori qualificati mercoledì 11 dicembre.
La conferenza, organizzata da iAccess Alpha, presenta aziende raccomandate da una rete di investitori e segue un formato di due giorni con webcast aziendali nel primo giorno e incontri di gestione individuali nel secondo giorno.
Anixa Biosciences (NASDAQ: ANIX), una empresa biotecnológica especializada en el tratamiento y la prevención del cáncer, ha anunciado su participación en la iAccess Alpha Virtual Best Ideas Winter Conference 2024. El evento se llevará a cabo el 10 y 11 de diciembre de 2024.
El Dr. Amit Kumar, CEO de Anixa, realizará una presentación el martes 10 de diciembre a las 2:00 p.m. EST. El equipo de gestión de la empresa estará disponible para reuniones individuales con inversores calificados el miércoles 11 de diciembre.
La conferencia, organizada por iAccess Alpha, presenta empresas recomendadas por una red de inversores y sigue un formato de dos días, con webcasts de la empresa el primer día y reuniones de gestión uno a uno el segundo día.
Anixa Biosciences (NASDAQ: ANIX), 암 치료와 예방을 전문으로 하는 생명공학 회사가 iAccess Alpha Virtual Best Ideas Winter Conference 2024에 참가한다고 발표했습니다. 이 행사는 2024년 12월 10일과 11일에 열릴 예정입니다.
Anixa의 CEO인 Amit Kumar 박사가 12월 10일 화요일 오후 2시(EST)에 발표를 할 것입니다. 회사의 경영진은 12월 11일 수요일에 자격을 갖춘 투자자와의 일대일 미팅을 위해 대기 중입니다.
iAccess Alpha에서 주최하는 이 회의는 투자자 네트워크에서 추천한 회사들을 특징으로 하며 첫날에는 회사 웹캐스트, 둘째 날에는 경영진 일대일 미팅으로 구성된 2일 형식을 따릅니다.
Anixa Biosciences (NASDAQ: ANIX), une entreprise biotechnologique spécialisée dans le traitement et la prévention du cancer, a annoncé sa participation à la iAccess Alpha Virtual Best Ideas Winter Conference 2024. L'événement se déroulera les 10 et 11 décembre 2024.
Dr. Amit Kumar, PDG d'Anixa, fera une présentation le mardi 10 décembre à 14h00 EST. L'équipe de direction de l'entreprise sera disponible pour des rencontres individuelles avec des investisseurs qualifiés le mercredi 11 décembre.
La conférence, organisée par iAccess Alpha, met en avant des entreprises recommandées par un réseau d'investisseurs et suit un format de deux jours, avec des webcasts d'entreprise le premier jour et des réunions individuelles de gestion le deuxième jour.
Anixa Biosciences (NASDAQ: ANIX), ein Biotechnologieunternehmen, das sich auf die Behandlung und Vorbeugung von Krebs spezialisiert hat, hat seine Teilnahme an der iAccess Alpha Virtual Best Ideas Winter Conference 2024 bekannt gegeben. Die Veranstaltung findet am 10. und 11. Dezember 2024 statt.
Dr. Amit Kumar, CEO von Anixa, wird am Dienstag, den 10. Dezember, um 14:00 Uhr EST eine Präsentation halten. Das Management-Team des Unternehmens steht am Mittwoch, den 11. Dezember, für persönliche Meetings mit qualifizierten Investoren zur Verfügung.
Die von iAccess Alpha veranstaltete Konferenz umfasst Unternehmen, die von einem Investoren-Netzwerk empfohlen werden, und folgt einem zweitägigen Format mit Unternehmens-Webcasts am ersten Tag und persönlichen Management-Meetings am zweiten Tag.
- None.
- None.
Dr. Amit Kumar, CEO of Anixa, is scheduled to present on Tuesday, December 10th at 2:00 p.m. Eastern Standard Time. To register and access the presentation, please visit https://www.webcaster4.com/Webcast/Page/3074/51704.
Management will also be available for one-on-one meetings with approved qualified investors on Wednesday, December 11th. To register for a one-on-one meeting, please visit the conference website at https://www.iaccessalpha.com/home.
iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by a network of investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-iaccess-alpha-virtual-best-ideas-winter-conference-2024-on-december-10-302321961.html
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa Biosciences (ANIX) presenting at the iAccess Alpha Winter Conference 2024?
How can investors attend Anixa's (ANIX) presentation at the iAccess Alpha Conference?
What is the format of the iAccess Alpha Conference where Anixa (ANIX) is presenting?
Will Anixa Biosciences (ANIX) be available for individual investor meetings?
